NO934130L - Tumoravvisningsantigenforloepere, tumoravvisningsantigener samt anvendelse derav - Google Patents

Tumoravvisningsantigenforloepere, tumoravvisningsantigener samt anvendelse derav

Info

Publication number
NO934130L
NO934130L NO934130A NO934130A NO934130L NO 934130 L NO934130 L NO 934130L NO 934130 A NO934130 A NO 934130A NO 934130 A NO934130 A NO 934130A NO 934130 L NO934130 L NO 934130L
Authority
NO
Norway
Prior art keywords
tumor rejection
antigens
tumor
antigen precursors
cells
Prior art date
Application number
NO934130A
Other languages
English (en)
Other versions
NO934130D0 (no
NO315051B1 (no
Inventor
Thierry Boon
Der Bruggen Pierre Van
Den Eynde Benoit Van
Pel Aline Van
Plaen Etienne De
Christophe Lurquin
Patrick Chomez
Catia Traversari
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/764,364 external-priority patent/US5327252A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO934130D0 publication Critical patent/NO934130D0/no
Publication of NO934130L publication Critical patent/NO934130L/no
Publication of NO315051B1 publication Critical patent/NO315051B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19934130A 1991-05-23 1993-11-16 Tumoravvisningsantigenforlöpere, tumoravvisningsantigener samt anvendelse derav NO315051B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70570291A 1991-05-23 1991-05-23
US72883891A 1991-07-09 1991-07-09
US07/764,364 US5327252A (en) 1990-09-21 1991-09-23 Print evaluation apparatus
US07/807,043 US5342774A (en) 1991-05-23 1991-12-12 Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
PCT/US1992/004354 WO1992020356A1 (en) 1991-05-23 1992-05-22 Tumor rejection antigen precursors, tumor rejection antigens and uses thereof

Publications (3)

Publication Number Publication Date
NO934130D0 NO934130D0 (no) 1993-11-16
NO934130L true NO934130L (no) 1993-11-23
NO315051B1 NO315051B1 (no) 2003-06-30

Family

ID=27505492

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19934130A NO315051B1 (no) 1991-05-23 1993-11-16 Tumoravvisningsantigenforlöpere, tumoravvisningsantigener samt anvendelse derav

Country Status (13)

Country Link
US (1) US5342774A (no)
EP (1) EP0595838B1 (no)
JP (1) JP3484459B2 (no)
AT (1) ATE279514T1 (no)
CA (2) CA2307317C (no)
DE (1) DE69233435T2 (no)
DK (1) DK0595838T3 (no)
ES (1) ES2225818T3 (no)
FI (1) FI117555B (no)
IL (1) IL101963A (no)
NO (1) NO315051B1 (no)
PT (1) PT100515B (no)
WO (1) WO1992020356A1 (no)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US5541104A (en) * 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DE69333670T2 (de) * 1992-08-31 2005-03-10 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
PT1025849E (pt) 1992-12-22 2002-09-30 Ludwig Inst Cancer Res Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
WO1994016713A1 (en) * 1993-01-22 1994-08-04 Ludwig Institute For Cancer Research Method for identifying and treating individuals bearing cancer cells that express hla-c-clone 10/mage-1
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5877017A (en) * 1993-06-17 1999-03-02 Ludwig Institute For Cancer Research Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
DE69533295T3 (de) * 1994-02-16 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
US5512437A (en) * 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US5763165A (en) * 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
CA2184482A1 (en) * 1994-03-01 1995-09-08 Etienne De Plaen Determination of cancerous conditions by mage gene expression
US5512444A (en) * 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
CA2188432C (en) 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5997870A (en) 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
US5589334A (en) * 1994-06-03 1996-12-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof
US5834245A (en) * 1994-07-29 1998-11-10 Cancer Institute PRLTS proteins and DNA's encoding the same
JPH10511639A (ja) * 1994-09-30 1998-11-10 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 腫瘍拒絶抗原前駆体または腫瘍拒絶抗原を含有する組成物ならびにアジュバント及び／又は成長因子
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
ES2154738T3 (es) 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7635479B2 (en) * 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5759783A (en) * 1995-03-14 1998-06-02 Ludwig Institute For Cancer Research Method of screening for cancer by detecting messenger RNA for a MAGE-XP gene
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US6017705A (en) * 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
US5939526A (en) * 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6140464A (en) * 1995-06-07 2000-10-31 Ludwig Institute For Cancer Research Nonapeptides that bind a HLA-A2.1 molecule
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
JPH11508767A (ja) * 1995-06-29 1999-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ マウス腫瘍拒絶抗原前駆体ｓｍａｇｅ−３をコードする単離核酸分子
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US7501501B2 (en) * 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
AP964A (en) * 1996-02-21 2001-05-11 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunisation.
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US7297331B2 (en) * 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
EP0910646A1 (en) * 1996-06-25 1999-04-28 The Ludwig Institute for Cancer Research Brain glycogen phosphorylase cancer antigen
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
JP2001517206A (ja) 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
US5912143A (en) * 1996-12-27 1999-06-15 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a human mage protein homolog
US6794131B1 (en) * 1998-01-27 2004-09-21 Ludwig Institute For Cancer Research Lage-1 tumor associated nucleic acids
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US5879892A (en) 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
EP0996857B1 (en) * 1997-07-17 2009-09-09 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US6210886B1 (en) 1998-02-04 2001-04-03 Ludwig Institute For Cancer Research Method for diagnosing multiple myeloma by determining tumor rejection antigen precursors
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US5905145A (en) * 1998-03-06 1999-05-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7001999B1 (en) 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
CA2351889A1 (en) * 1998-11-12 2000-05-18 Cell Science Therapeutics, Inc. Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
EP1194542A1 (en) * 1999-03-02 2002-04-10 Ludwig Institute For Cancer Research Cloning of cdna of mage's 5,8,9 and 11 and their uses in diagnosis of cancer
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
CA2370000A1 (en) * 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US6448073B1 (en) 2000-01-28 2002-09-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2001085932A2 (en) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
US7393657B2 (en) 2001-04-12 2008-07-01 Imperial College Innovations Limited Diagnosis and treatment of cancer: I
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
PT1496939E (pt) 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
CA2496888A1 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
EP2292638A3 (en) 2002-09-27 2011-03-23 Ludwig Institute For Cancer Research MAGE-C2 antigenic peptides and uses thereof
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
ES2661082T3 (es) 2003-01-30 2018-03-27 Survac Aps Péptidos derivados de survivina y uso de los mismos
PT1691824E (pt) 2003-11-19 2009-05-28 Merck Patent Gmbh Proteínas pertencentes à família bcl-2 e seus fragmentos e sua utilização em doentes de cancro
US20080063652A1 (en) * 2004-03-29 2008-03-13 Cytomatrix, Llc Methods for Production of Regulatory T Cells and Uses Thereof
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
KR101076578B1 (ko) 2004-06-23 2011-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 2입자 착물을 이용한 생물학적 분자의 검출을 위한 방법 및조성물
CA2592968A1 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
SG158154A1 (en) * 2004-12-29 2010-01-29 Mannkind Corp Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
EP1851308B1 (en) * 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
JP2008528643A (ja) 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
JP5170976B2 (ja) 2006-04-11 2013-03-27 株式会社イミュノフロンティア タンパク質複合体およびその製造方法
EP2052076A4 (en) 2006-08-02 2010-07-14 Newsouth Innovations Pty Ltd METHOD FOR IDENTIFYING ANY ANTIGEN-ACTIVATED, CD8-EXPRESSING CD4 + CD25 + T-CELLS
JP2009545330A (ja) * 2006-08-04 2009-12-24 ザ トラスティーズ オブ ザ ユニバーシティー オブ ぺンシルべニア Ｉｇｅ依存性疾患を治療するための方法および組成物
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2061800B1 (en) * 2006-08-15 2015-07-29 The Trustees of the University of Pennsylvania Compositions comprising hmw-maa and fragments thereof, and methods of use thereof
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700579A1 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2328923B1 (en) 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Cd133 epitopes
DK2403935T3 (en) 2009-03-04 2017-09-11 Univ Pennsylvania COMPOSITIONS CONTAINING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF
EA021100B1 (ru) 2009-03-17 2015-04-30 МДхХЭЛС СА Усовершенствованное определение экспрессии генов
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
EP2683400A4 (en) 2011-03-11 2014-09-17 Advaxis ADJUVANZIA ON LISTERIA BASE
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
EP2956544B1 (en) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Cancer vaccines and vaccination methods
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2019006003A1 (en) 2017-06-27 2019-01-03 The Trustees Of Princeton University COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
EP3743093A1 (en) 2018-01-26 2020-12-02 Cambridge Enterprise Limited Peptide exchange protein
WO2020012486A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
US20210379109A1 (en) 2018-08-24 2021-12-09 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
JP2022541742A (ja) 2019-07-11 2022-09-27 カール メディカル リミテッド ヘテロダイマーおよびその使用方法
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141742A (en) * 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5185432A (en) * 1986-02-26 1993-02-09 Oncogen Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells

Also Published As

Publication number Publication date
EP0595838A1 (en) 1994-05-11
CA2307317A1 (en) 1992-11-26
FI935174A0 (fi) 1993-11-22
DK0595838T3 (da) 2005-01-31
ES2225818T3 (es) 2005-03-16
IL101963A (en) 2004-03-28
CA2307317C (en) 2006-07-18
FI935174A (fi) 1993-11-22
US5342774A (en) 1994-08-30
JP3484459B2 (ja) 2004-01-06
CA2109727C (en) 2000-07-25
WO1992020356A1 (en) 1992-11-26
EP0595838A4 (en) 1995-10-25
DE69233435T2 (de) 2005-03-03
EP0595838B1 (en) 2004-10-13
PT100515A (pt) 1993-08-31
NO934130D0 (no) 1993-11-16
NO315051B1 (no) 2003-06-30
FI117555B (fi) 2006-11-30
DE69233435D1 (de) 2004-11-18
IL101963A0 (en) 1992-12-30
PT100515B (pt) 1999-08-31
CA2109727A1 (en) 1992-11-26
ATE279514T1 (de) 2004-10-15
JPH06511144A (ja) 1994-12-15

Similar Documents

Publication Publication Date Title
NO934130L (no) Tumoravvisningsantigenforloepere, tumoravvisningsantigener samt anvendelse derav
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DK0845032T3 (da) Isolerede nucleinsyremolekyler, peptider, der danner komplekser med MHC-molekyler HLA-A2, samt anvendelser
PT1203817E (pt) Compostos e metodos para imunoterapia e le diagnostic de tuberculose
FI956019A (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
DE69830663D1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
DE69727966D1 (de) Ein mit krebs assoziiertes antigen kodierendes isoliertes nukleinsäuremolekül, das antigen selbst, und dessen verwendungen
ATE386106T1 (de) Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung
DK251890A (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
ZA983488B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursors mage-c1 and mage-c2 and uses thereof
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
DK102589A (da) Antigen, der genkendes af mca 16-88
BR9911609A (pt) Proteìnas e genes de moraxella catarrhalis, antìgenos, anticorpos e usos
DE69616288D1 (de) Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
IT1213576B (it) Composizione polipeptidica utile per la preparazione di vaccini antimalaria e di kits diagnostici per la determinazione di anticorpi antimerozoite.
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer

Legal Events

Date Code Title Description
MK1K Patent expired